Navigation Links
ABAXIS Realigns North American Medical Sales and Marketing
Date:4/7/2009

UNION CITY, Calif., April 7 /PRNewswire-FirstCall/ -- Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis instruments for both the medical and veterinary markets, announced a reorganization of its North American sales and marketing organization resulting from a strategic review of the company's medical business. As a part of this reorganization, Christopher M. Bernard, Vice President of North American Medical Sales and Marketing, has ceased to be an employee of the company.

Abaxis' Medical Area Sales Directors, Mike Petrunich and Matt Rapp, will continue to be responsible for managing and growing the field sales teams. Rick Betts, Director of Medical Marketing, will coordinate their efforts with the in-house marketing team and all will report to Clint Severson, chief executive officer, until a successor to Mr. Bernard is named. The Company has hired and retained a recruiting firm to find a successor; eligible candidates could come from inside or outside the company.

About Abaxis

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

Safe Harbor

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. Specific forward-looking statements contained in this press release are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the company's ability to recruit and retain sales and marketing personnel, the market acceptance of the Company's products and the continuing development of its products, risks associated with manufacturing and distributing its products on a commercial scale, risks associated with entering the human diagnostic market on a larger scale, general market conditions, competition and other risks detailed from time to time in Abaxis' periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statement was made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

    Contact:   Clint Severson             Lytham Partners, LLC
               Chief Executive Officer    Joe Dorame, Robert Blum and Joe Diaz
               Abaxis, Inc.               602-889-9700
               510-675-6500


'/>"/>
SOURCE Abaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abaxis, Inc. to Attend Lazard Capital Markets Medical Technologies Conference
2. Abaxis, Inc. to Present at Sidoti & Companys Thirteenth Annual New York Emerging Growth Institutional Investor Forum
3. Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2009
4. ABAXIS Announces Launch of Two New Products at the NAVC
5. ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd.
6. Abaxis, Inc. to Present at Sidoti & Companys Sixth Annual Palm Beach Emerging Growth Institutional Investor Forum
7. Abaxis, Inc. to Present at Needham & Companys Eleventh Annual Growth Stock Conference
8. Abaxis Point-of-Care Test Panels Gain FDA CLIA-Waived Status
9. Abaxis, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
10. Abaxis to Report Second Quarter Fiscal 2009 Financial Results Monday, October 27, 2008
11. Abaxis, Inc. to Present at CL Kings Sixth Annual Best Ideas Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 2017 , ... The Ellis Agency, an eastern Georgie provider of insurance management ... wide charity event with the goal of bringing in support for epilepsy patients in ... with epilepsy, recently launched a charity campaign of her own by donating her birthday ...
(Date:7/21/2017)... ... , ... Fresh Wave® IAQ today announced the launch of its innovative ... at the APPA 2017 Annual Conference and Exhibition in Booth #414. , ... the use of harsh chemicals, Fresh Wave IAQ Smoke Away Air & Fabric Liquid ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm ... the contents of its ginger ale for allegedly containing no ginger. Dr. Pepper produces ... Snapple Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how ... their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. ... on Kickstarter on Monday, July 21st. , The kit uses colorful, engaging and ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... cruciate ligament (ACL) offer patients improved quality of life five years after injury, ... Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed patients for ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
Breaking Medicine Technology: